News News

CONTACT:

Sirnaomics, Inc.
Michael Molyneaux MD MBA
Chief Medical Officer
michaelmolyneaux@sirnaomics.com

ICR Healthcare

Investors: Stephanie Carrington
Tel: +1 646 277 1282
Stephanie.Carrington@icrinc.com

Media: Mark Corbae
Tel: 203-682-8288
Email: Mark.Corbae@icrinc.com

February 10, 2020 Sirnaomics’ siRNA Therapeutic Candidate, STP705, Granted Orphan Drug Designation By US FDA for Treatment of Hepatocellular Carcinoma

Sirnaomics, Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the…

Wuhan
January 24, 2020 Sirnaomics Advances RNAi-Based Prophylactics and Therapeutics to Battle SARI Caused by 2019-nCoV

Sirnaomics Inc. (“Sirnaomics”), a leading biopharmaceutical company in discovery and development of novel RNAi therapeutics, announced today…

January 13, 2020 Sirnaomics and Junshi Biosciences Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Tuoyi and RNAi in China and US

Gaithersburg, MD, USA, and Shanghai, China, January 13, 2020 — Sirnaomics Inc. (“Sirnaomics”), a leading biopharmaceutical company…

Innov Sir2
January 7, 2020 Sirnaomics and Innovent Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Sintilimab and RNAi in the US

Sirnaomics Inc. (“Sirnaomics”), a leading biopharmaceutical company in discovery and development of RNAi therapeutics against cancer and…

Aasld
November 1, 2019 Sirnaomics to Present Preclinical STP705 Data Suggesting Reduction in Liver Fibrosis at AASLD Liver Meeting

Sirnaomics Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and…

1 2 3 9